Abstracts tagged "skin and systemic lupus erythematosus (SLE)"

Abstract Number: 2757 • 2017 ACR/ARHP Annual Meeting
Kidney and Skin Single-Cell RNA Sequencing in Lupus Nephritis Provides Mechanistic Insights and Novel Potential Biomarkers
Evan Der¹, Hemant Suryawanshi², Saritha Ranabothu³, Beatrice Goilav⁴, H. Michael Belmont⁵, Peter M. Izmirly⁶, Nicole Bornkamp⁵, Nicole Jordan⁷, Tao Wang¹, Ming Wu⁶, Judith A. James⁸, Joel M. Guthridge⁹, Soumya Raychaudhuri¹⁰, Thomas Tuschl¹¹, Jill P. Buyon¹² and Chaim Putterman¹³, ¹Albert Einstein College of Medicine, Bronx, NY, ²The Rockefeller University, New York, NY, ³Nephrology, Children's Hospital at Montefiore, Bronx, NY, ⁴Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁵Medicine, New York University School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷Montefiore Medical Center, New York, NY, ⁸Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Rockefeller University, New York, NY, ¹²Rheumatology, New York University School of Medicine, New York, NY, ¹³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Classification and treatment decisions in lupus nephritis (LN) are largely based on renal histology. Single-cell RNAseq (scRNAseq) analysis may accurately differentiate types of renal…
Abstract Number: 1769 • 2015 ACR/ARHP Annual Meeting
Role of Topical Administration of Peptidylarginine Deiminase Inhibitors in Murine Lupus
Erica Moore¹, Huw Lewis², Carolyne K. Smith¹, Venkataraman Subramaniam³, Victoria Hoffmann⁴, Paul Thompson⁵ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Immuno Inflammation, GSK, Stevenage, United Kingdom, ³University of Massachusetts, Boston, MA, ⁴ORS, National Institutes of Health, Bethesda, MD, ⁵University of Massachusetts, Worcester, MA
Background/Purpose: Peptidylarginine deiminases (PADs), specifically PAD4, have recently been implicated in the pathogenesis of systemic lupus erythematosus (SLE) through their role in citrullinating histones in…
Abstract Number: 1649 • 2014 ACR/ARHP Annual Meeting
High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis
Marco Ulises Martinez-Martinez¹, Maria Daniela De Avila², Mario Perales³, Lourdes Baranda⁴, Susana Román Acosta⁵, Jaime Antonio Borjas García⁵ and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Regional Unit Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³Regional Unit of Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁴Regional Unit of Rheumatology and Osteoposis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁵Nephrology Department, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Background/Purpose: Deposit of different classes of immunoglobulins is the main feature of lupus nephritis;1 because of its high specificity, a patient is classified as having…
Abstract Number: 2512 • 2013 ACR/ARHP Annual Meeting
Smoking Is Associated With More Severe Skin Disease In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
Victoria P. Werth¹, Munther A. Khamashta², Gabor G. Illei³, Stephen Yoo³, Liangwei Wang⁴ and Warren Greth³, ¹Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁴Biostatistics, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: The influence of smoking on the severity of cutaneous manifestations in adults with moderate to severe SLE was assessed in an ongoing international, multi-center,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].